Palladium-103 Seed Implant and Single Daily Dosing of Uroxatral Vs. Twice Daily Dosing of Flomax- A 3 Month Retrospective Efficacy Analysis
Information source: Dattoli Cancer Center and Brachytherapy Research Institute
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Prostate Cancer Patients Undergoing External Radiation and Seed Implantation
Phase: N/A
Status: Completed
Sponsored by: Dattoli Cancer Center and Brachytherapy Research Institute Official(s) and/or principal investigator(s): Michael J Dattoli, MD, Principal Investigator, Affiliation: Dattoli Cancer Center and Brachytherapy Research Institute
Summary
In the past ten years, newer drugs with more selective affinity for the alpha-receptor have
been introduced. Alfuzosin (Uroxatral) and Tamulosin(Flomax are two second generation
alpha-blockers. In the course of our clinical proctice, both drugs have been used routinely.
This retrospective comparison is intended to be a priliminary comparison of their
effectiveness and side effects.
Clinical Details
Official title: Palladium-103 Seed Implant and Single Daily Dosing of Uroxatral Vs Twice Daily Dosing of Flomax-A 3 Month Retrospective Efficacy Analysis
Study design: Observational Model: Defined Population, Time Perspective: Longitudinal
Eligibility
Minimum age: 45 Years.
Maximum age: 80 Years.
Gender(s): Male.
Criteria:
Inclusion Criteria:
- Males age 45-80 years
- Diagnosis of prostate cancer
- Status post IMRT and Palladium-103 seed implantation and initiated alpha blocker
therapy with alfuzosin10mg daily or tamulosin 0. 4mg bid at time of seed implantation
- Baseline AUA score< or =12
- May be on antiandrogenand/or alpha reductase therapy
- Patients receiving IMRT followed by Palladium-103 Brachytherapy implantation as the
primary therapy for prostate cancer with curatives intent -
Exclusion Criteria:
- History of insulin-dependent diabetes
- Uncontrolled hypertention
- History of symptomtic hypotension (including syncope and dizziness)
- Pre-existing obstructive uropathy based on history of BPH and or Acute Urinary
Retention
- Pre-existing prostatitis either continuous or intermittent
- Concurrent use of any other anticholinergics
- previous or concurrent usage of LHRH agonist
Locations and Contacts
Dattoli Cancer Center and Brachytherapy Research Institute, Sarasota, Florida 34237, United States
Additional Information
Starting date: November 2005
Last updated: December 6, 2005
|